CLX DER 622
Alternative Names: CLX-DER-622Latest Information Update: 28 Apr 2024
At a glance
- Originator Cellix Bio
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rosacea
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Rosacea in India
- 04 Mar 2020 Cellix Bio has multiple international patents, including in the US, covering its pipeline candidates (Cellix Bio website, March 2020)
- 04 Mar 2020 Preclinical trials in Rosacea in India (Cellix Bio pipeline, March 2020)